Diamyd Medical
15.78
SEK
-0.75 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-0.75%
-12.04%
-4.01%
+30.85%
-5.51%
+17.76%
+1.01%
-14.49%
+423.09%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Read moreMarket cap
1.64B SEK
Turnover
1.21M SEK
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Financial calendar
9.4
2025
Interim report Q2'25
25.6
2025
Interim report Q3'25
8.10
2025
Annual report '25
ShowingAll content types
Diamyd Medical AB: Diamyd[ ]Medical's CFO to leave in 2025
Diamyd Medical AB: Diamyd[ ]Medical announces expanded financial support from Breakthrough T1D
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools